FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to the use of an antibody specific to CD19 and fludarabine to produce a synergistic combination for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
EFFECT: invention effectively treats non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
13 cl, 11 tbl, 3 ex
Authors
Dates
2018-08-17—Published
2012-08-14—Filed